Press release

Please fill in this form and return it to graduateschoolhealth@au.dk in Word format no later than three weeks prior to your defence.

Basic information

Name: Niels Sanderhoff Degn Email: nsd@dandrite.au.dk Phone: 51941437

Department of: Biomedicine

Main supervisor: Anders Nykjær

Title of dissertation: SorCS2 as a modifier of disease progression in Huntington´s disease

Date for defence: 14/3 2019 at (time of day): 14.00 Place: Aarhus University, Bartholins Allé, 8000 Aarhus C, William Scharff auditoriet

Press release (Danish)

Betydning af SorCS2 for sygdomsudviklingen i Huntingtons sygdom.

Huntingtons sygdom er en dominant nedarvet neurodegenerativ sygdom som er forårsaget af en mutation i huntingtin genet og især påvirker nervecellerne i hjerne strukturen striatum. Selv om årsagen til sygdommen er kendt, og diagnosen kan stilles ved genetisk testning mange år før symptomdebut, er der endnu ingen etableret sygdomsmodificerende behandling som patienterne kan tilbydes. Hvor tidligt i livet sygdommen debuterer afhænger primært af mutationen i huntingtin genet, men der er tegn på at andre gener også kan påvirke hvor hurtigt sygdommen udvikler sig. Mere viden om sådanne andre gener som påvirker sygdomsudviklingen kan derfor på langt sigt potentielt bedre mulighederne for at behandle sygdommen. Et nyt ph.d.-projekt fra Aarhus Universitet, Health har undersøgt betydningen af receptoren SorCS2 for sygdomsudviklingen i en model for Huntingtons i mus. Projektet er gennemført af Niels Sanderhoff Degn, der forsvarer det d. 14/3.
Han har undersøgt hvordan SorCS2 påvirker kommunikationen mellem nervecellerne i hjernebarken og stiatum, hvordan Huntingtons sygdom influerer på niveauet af SorCS2 og hvordan fejlfunktion af genet, der koder for SorCS2, forværrer sygdomsforløbet. Forsvaret af ph.d.-afhandlingen er offentligt og finder sted den 14/3 kl. 14 i William Scharff auditoriet, Aarhus Universitet, Bartolins Allé, 8000 Aarhus C. Titlen på projektet er ”SorCS2 as a modifier of disease progression in Huntington´s disease”. Yderligere oplysninger: Ph.d.-studerende Niels Sanderhoff Degn, e-mail: nsd@dandrite.au.dk. Tlf: +4551941437.

Bedømmelsesudvalg:

Associate Professor Olav M Andersen
Department of Biomedicine, Aarhus University, Denmark

Associate Professor Anne Nørremølle Department of Cellular and Molecular Medicine Section of Neurogenetics, University of Copenhagen

Professor Thomas E Willnow
Max-Delbrück-Center for Molecular Medicine, Germany

Press release (English)

Effect of SorCS2 on disease progression in Huntington's disease.

Huntington's disease is a dominantly inherited neurodegenerative disease that is caused by a mutation in the huntingtin gene, and particularly affects the nerve cells of the brain structure

striatum. Although the cause of the disease is known, and the diagnosis can be esthablished by genetic testing several years before symptom onset, there is as yet no established disease-modifying treatment that the patients can be offered. Age of onset of the disease depends primarily on the mutation in the huntingtin gene, but there is evidence suggesting that other genes may also modify the disease progression. More knowledge about such disease modifying genes could improve the possibilities of treating the disease in the long term. A new PhD project from Aarhus University, Health, has investigated the effect of the SorCS2 receptor on disease progression in a Huntington's disease mouse model. The project was carried out by Niels Sanderhoff Degn, who is defending his dissertation on 14/3.
He has investigated how SorCS2 affects the long-term potentiation of the connections between nerve cells in the cerebral cortex and the stiatum, how Huntington's disease affects the level of SorCS2 in the striatum and how complete lack of the SorCS2 gene affects disease progression in a Huntington's disease mouse model. The defence is public and takes place on 14/3 at 14.00 in the William Scharff auditorium, Aarhus University, Bartolins Allé, 8000 Aarhus C. The title of the project is "SorCS2 as a modifier of disease progression in Huntington's disease". For more information, please contact PhD student Niels Sanderhoff Degn, e-mail: nsd@dandrite.au.dk. Phone: +4551941437.

Assessment committee:

Associate Professor Olav M Andersen
Department of Biomedicine, Aarhus University, Denmark

Associate Professor Anne Nørremølle Department of Cellular and Molecular Medicine Section of Neurogenetics, University of Copenhagen

Professor Thomas E Willnow
Max-Delbrück-Center for Molecular Medicine, Germany

Permission

By sending in this form:

- I hereby grant permission to publish the above Danish and English press releases.
- I confirm that I have been informed that any applicable inventions shall be treated confidentially and shall under no circumstances whatsoever be published, presented or mentioned prior to submission of a patent application, and that I have an obligation to inform my head of department and the university's Patents Committee if I believe I have made an invention in connection with my work. I also confirm that I am not aware that publication violates any other possible holders of a copyright.